(3R,5S,6R)-6-[5-[3-[5-[(2R,4R,5R)-4,5-dihydroxy-6-(hydroxymethyl)-3-methyloxan-2-yl]oxypentoxy]-2-[5-[(2R,3S,5R)-4,5-dihydroxy-6-(hydroxymethyl)-3-methyloxan-2-yl]oxypentoxymethyl]-2-methylpropoxy]pentoxy]-2-(hydroxymethyl)-5-methyloxane-3,4-diol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3R,5S,6R)-6-[5-[3-[5-[(2R,4R,5R)-4,5-dihydroxy-6-(hydroxymethyl)-3-methyloxan-2-yl]oxypentoxy]-2-[5-[(2R,3S,5R)-4,5-dihydroxy-6-(hydroxymethyl)-3-methyloxan-2-yl]oxypentoxymethyl]-2-methylpropoxy]pentoxy]-2-(hydroxymethyl)-5-methyloxane-3,4-diol
• 化学式: C₄₁H₇₈O₁₈
• 分子量: 859.0
• InChiKey: NXOZMXCWMRMTML-YYOUVTLDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  59
• 可旋转键数：
  30
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  265
• 氢给体数：
  9
• 氢受体数：
  18

文献信息

• Compositions and Methods for Inhibition of Expression of Protein C (PROC) Genes
  申请人：Toudjarska Ivanka

  公开号：US20140142162A1

  公开（公告）日：2014-05-22

  The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC. At least one nucleotide of the dsRNA can be a modified nucleotide, e.g., a 2-0-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group. Other examples of modified nucleotides include a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxymodified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide. A dsRNA of the invention can include one or more of any of these modified nucleotides.
• KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20160340679A1

  公开（公告）日：2016-11-24

  The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the ketohexokinase (KHK) gene, and methods of using such RNAi agents to inhibit expression of KHK and methods of treating subjects having a KHK-associated disorder, e.g., liver disease (e.g., fatty liver, steatohepatitis), dyslipidemia (e.g., hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (e.g., insulin resistance, diabetes), cardiovascular disease (e.g., hypertension, endothelial cell dysfunction), kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.